Compare Ascendis Pharma A/S (ASND) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Kinder Morgan Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Kinder Morgan Inc trades at $32.32 (market cap $71.46B). The key difference: Kinder Morgan Inc is far larger — about 4× Ascendis Pharma A/S's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KMI | |
|---|---|---|
Market Cap | $17.74B | $71.46B |
Sector | Health | Energy |
52-Week High | $277.18 | $34.31 |
52-Week Low | $163.32 | $25.84 |
Enterprise Value | $18.11B | $103.34B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Kinder Morgan (KMI) trades at $32.12, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $0.48 EPS, and maintains a solid dividend. Revenue grew to $16.94B in 2025, with net income margin improving to 18.92%. Recent news highlights KMI's exposure to natural gas infrastructure growth and stable cash flows from fee-based contracts.
KMI offers a balanced risk-reward profile with steady cash flow and dividend appeal, supported by a $10.1B project backlog. Risks include commodity price volatility and high debt levels. Analyst consensus is mixed but leans positive, with 47% buy ratings. The stock's valuation at a P/E of 21.56 is reasonable given earnings growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
